

Lupin and Amman Pharma sign agreement for Ranibizumab Biosimilar

10 November 2023 | News

Pioneering access to complex ophthalmic biosimilar medicine in the MENA Region



Mumbai-based pharma major Lupin has partnered with Jordan-headquartered Amman Pharmaceuticals Industries, a leading pharmaceutical manufacturer with operations across the Middle East and North Africa (MENA) region and other global markets, for exclusive marketing and commercialisation of Ranibizumab, a biosimilar of Lucentis®, in the Middle East region, including select territories of Jordan, Saudi Arabia, UAE, Iraq, Lebanon, and other GCC countries.

Ranibizumab is a recombinant humanised IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A (VEGF-A). Its indications encompass the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Edema Following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), Diabetic Retinopathy (DR) and Myopic Choroidal Neovascularisation (mCNV).

“Our aim is to be at the forefront of transforming patient’s lives and building a healthier, brighter future for all,” said Nilesh Gupta, Managing Director, Lupin.

“We aim to empower patients by offering timely and widespread access to cutting-edge biologic medication at affordable costs. Our successful development of biosimilar Ranibizumab stands as testament to this commitment,” said Dr Cyrus Karkaria, President Biotechnology, Lupin.

Dr Fadi Alatrash, General Manager of Amman Pharma said, “This partnership is aligned with our mission to provide high-quality products and access to advanced biosimilars to patients in the region. It also expands our biosimilar portfolio and

strengthens our position in the niche ophthalmology market.”